Avacta Group Management
Management criteria checks 1/4
Avacta Group's CEO is Chris Coughlin, appointed in May 2024, has a tenure of less than a year. directly owns 0.014% of the company’s shares, worth £23.76K. The average tenure of the management team and the board of directors is 1.8 years and 0.5 years respectively.
Key information
Chris Coughlin
Chief executive officer
UK£53.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.01% |
| Management average tenure | 1.8yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Avacta Group Plc's (LON:AVCT) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Nov 19
Is Avacta Group (LON:AVCT) Using Debt Sensibly?
Oct 29Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up
Sep 05Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet
Jun 21Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding
Feb 23Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely
Aug 05Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?
Jun 22We're Hopeful That Avacta Group (LON:AVCT) Will Use Its Cash Wisely
Oct 20This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation
Jun 22Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans
Jun 20Avacta Group Plc (LON:AVCT) Insiders Have Been Selling
Feb 18CEO
Chris Coughlin (54 yo)
less than a year
Tenure
UK£53,000
Compensation
Dr. Christina M. Coughlin, also known as Chris, BS, MD, PH D., was Head of Research and Development of Avacta Group Plc from February 1, 2024 and serves as its Chief Executive Officer from May 01, 2024 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Interim Chief Medical Officer and Director | less than a year | UK£53.00k | 0.014% £ 23.8k | |
| CFO & Company Secretary | 8.9yrs | UK£409.00k | 0.0022% £ 3.9k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Group In-House Counsel | no data | no data | no data | |
| Group Communications Director | 3.9yrs | no data | no data | |
| Chief Operating Officer of Diagnostics | 8.3yrs | UK£69.00k | no data | |
| Chief Commercial Officer of Diagnostics | 1.9yrs | no data | no data | |
| Chief Operating Officer of Therapeutics Division | 1.8yrs | no data | no data | |
| Joint Managing Director of Launch Diagnostics | 1.7yrs | no data | no data | |
| Joint Managing Director of Launch Diagnostics | 1.7yrs | no data | no data | |
| Chief Business Officer of Therapeutics | less than a year | no data | no data | |
| Chief Operating Officer of Coris BioConcept | 1.8yrs | no data | no data |
1.8yrs
Average Tenure
54yo
Average Age
Experienced Management: AVCT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Interim Chief Medical Officer and Director | 2.8yrs | UK£53.00k | 0.014% £ 23.8k | |
| Independent Non-Executive Director | 11.3yrs | UK£47.00k | 0.029% £ 51.0k | |
| Non Executive Director | less than a year | no data | no data | |
| Non-Executive Independent Chairman | 1.5yrs | UK£26.00k | 0.011% £ 19.0k | |
| Independent Non-Executive Director | 3.3yrs | UK£53.00k | no data | |
| Independent Non-Executive Director | 4.8yrs | UK£47.00k | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Chairman of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
0.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: AVCT's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avacta Group Plc is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vadim Alexandre Khalil | Daniel Stewart & Company |
| Lorenza Castellon | Equity Development Limited |
| Paul Cuddon | Numis Securities Ltd. |